Novo Nordisk’s Wegovy Shows Superior Improvement in Liver Fibrosis and MASH Resolution in Phase III ESSENCE Trial

Trial Results:
Novo Nordisk's semaglutide (Wegovy) demonstrated statistically significant and superior improvement in liver fibrosis and resolution of metabolic dysfunction-associated steatohepatitis (MASH) in the Phase III ESSENCE trial.

Comparison to Rezdiffra:
Analysts noted that the results were comparable to Madrigal Pharmaceuticals' Rezdiffra, with similar improvements in fibrosis.

Primary Endpoints:
The trial achieved its primary endpoints by showing superior improvement in liver fibrosis with no worsening of steatohepatitis and resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo.

Safety Profile:
The safety profile of semaglutide was in line with previous trials, indicating it was safe and well-tolerated.

Regulatory Plans:
Novo Nordisk plans to file for regulatory approvals in the US and EU in the first half of 2025.

Detailed Results:
Detailed results from the ESSENCE trial will be presented at a scientific conference in 2024, with part 2 of the trial expected to read out in 2029.